Psychotropic drug

About: Psychotropic drug is a research topic. Over the lifetime, 2309 publications have been published within this topic receiving 54070 citations.

A decade of extreme oscillations in opioid control and availability: implications for public health in a Canadian setting.

Abstract: We comment on developments in and impacts of medical opioid control and availability in the province of British Columbia (Canada). Population-level dispensing of (strong) prescription opioids doubled in 2005–2011, yet subsequently declined by half 2011–2018 following implementation of various opioid control measures. Notwithstanding this inversion, BC has featured the highest population rates of opioid-related mortality and morbidity in Canada. The erratic opioid availability patterns presumably facilitated major increases in opioid misuse, morbidity, and mortality. Tangible benefits for pain care from increased medical opioid availability remain un-evidenced. Rather, recent decreases in medical opioid dispensing have not been matched by equivalent reductions in demand for (non-)medical use yet have coincided with widespread proliferation of toxic, illicit opioid supply and related major increases in opioid-related mortality. These developments appear to have undermined rather than benefitted public health and offer a poignant case study in ineffective psychotropic drug control and public health policy towards preventing similar experiences elsewhere.

On the Value of CNS, ANS and Behavioral Measures in Early Clinical Psychopharmacology

Abstract: The ever increasing number of newly developed potentially psychoactive compounds since 1952 resulted in a need for screening methods in early clinical pharmacology. The quantitative analysis of the human scalp-recorded EEG in combination with certain statistical procedures (called “quantitative pharmaco-EEG”) along with psychometric methods has been proven to mediate valuable objective and quantitative information about the effect of psychotropic drugs on their target organ— the human brain — and on human behavior (Fink, 1969, Saletu, 1976; Grunberger and Saletu, 1980). It seems possible to predict 1) if; 2) how; 3) in which dosage; 4) at which time a new compound will act, which will be shown by an example of a recently performed pharmaco-EEG and psychometric study with temazepam—a relatively new benzodiazepine with the advantage of a short half life and lack of active metabolites.

Integrated health care, use of psychotropic medications and soy products as alternative in patients who suffer from schizophrenia and metabolic syndrome

Abstract: There is a relationship between the increases of metabolic disorders in patients; whom are consuming medication to treat severe mental illnesses. There is also consensus in the relationship between the body fat distribution and cardiovascular disease, diabetes, use of psychotropic drug, among others. On the other hand, psychotropic medications have come to play an increasingly major role in the treatment of psychiatric disorders. However, many patients treated with psychotropic drugs tend to gain corporal weight and are sensitive to the diseases mentioned above. Fortunately, healthy and equilibrated food intake has been associated with the prevention of diseases. This review will address the effects of psychotropic medication intake and how this relates to obesity, risk of cardiovascular diseases in patients who suffer from severe mental illnesses. It will also evaluate the potential use of healthy diets using soy, and exercise to improve the well being of the patient. Existe una relacion entre el aumento de trastornos metabolicos en pacientes; quienes consumen medicamentos para tratar enfermedades mentales graves. Tambien hay consenso en la relacion que existe sobre la distribucion de la grasa corporal con enfermedades cardiovasculares, diabetes, el uso de drogas psicotropicas, entre otros. Por otro lado, el uso de sicotropicos ha llegado a desempenar un papel cada vez mas importante en el tratamiento de trastornos psiquiatricos. Sin embargo, muchos pacientes tratados con estas drogas, tienden al sobrepeso, haciendose sensible a estos riesgos. Afortunadamente, la ingesta de alimentos saludables y equilibrados se ha asociado con la prevencion de enfermedades. Esta revision dirigira a los efectos de la ingesta de medicacion con sicotropicos y como esto se relaciona con la obesidad, riesgo de enfermedades cardiovasculares en pacientes que sufren de enfermedades mentales graves. Tambien evaluara el uso potencial de las dietas saludables con soja y ejercicios para mejorar el bienestar del paciente.

Pharmacological studies on CS-430, a new psychotropic agent.

Abstract: 10-Bromo-11b-(2-fluorophenyl)-2,3,7,11b-tetrahydrooxazolo[3,2-d][1,4]benzodiazepin-6(5H)-one (CS-430) is a new psychotropic drug and has the following properties. The compound showed sleep-inducing effect at both 0.2 and 5 mg/kg (p.o.) in cynomolgus monkeys or at 3 mg/kg (p.o.) in rats. CS-430 showed selective conflict attenuating in rats or anticonvulsant effects in mice. Furthermore, CS-430 blocked non-discriminated (Sidman) avoidance response without severe impairment of the motor function but not discriminated (shuttle-box) avoidance response in rats. CS-430 also blocked selectively electroshock-induced fighting behavior of mice but not isolation-induced fighting behavior of mice and muricidal behavior induced by ablation of the olfactory bulbs. In addition, CS-430 produced specific potentiation of chlorprothixene-induced sleep and particular potentiation of thiopental sleep in mice. These effects of CS-430 were similar to those of nitrazepam, but differed from those of phenobarbital. The effect of CS-430 on the motor function was roughly 1/2 as potent as that of nitrazepam in the various tests.

Adherence with respect to medication management

Abstract: Medication has played a major role in the alleviation of pain and suffering with respect to psychiatric treatments. At least 66% to 75% of patients who receive psychotropic drugs for various conditions have a ≥ 50% decrease in their symptoms and approximately 35% have a remission. To achieve this improvement, one must adhere to the therapeutic regimen. Communication between the physician and patient is paramount to achieving this adherence. There are numerous etiologies of non-compliance, including stigma and shame in needing psychiatric treatment, specific beliefs about the meaning of medication and psychiatric treatment, and the fear of psychotropic drug side effects that may be disabling and can offset the therapeutic benefit. This article assesses strategies to improve adherence with medication and other psychiatric treatments, such as psychoeducation, psychotherapy, and behavioral and social service interventions. Exploring the meaning of illness and medications-including the risk-benefit ratio of taking the medication versus the alternatives; denial; the patient's motivation for treatment, and the patient's expectations for treatment-are all important in improving compliance and achieving a better outcome. This article examines ways to assess non-compliance, determine the reasons for non-compliance, and choose interventions to encourage compliance with treatment.